Literature DB >> 15721417

Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial.

Bradley J Monk1, Jianmin Wang, Samuel Im, Richard J Stock, William A Peters, P Y Liu, Rolland J Barrett, Jonathan S Berek, Luis Souhami, Perry W Grigsby, William Gordon, David S Alberts.   

Abstract

OBJECTIVE: To retrospectively analyze data from a previously reported randomized trial of either pelvic radiation (RT) or RT + chemotherapy (CT) in patients undergoing radical hysterectomy and pelvic lymphadenectomy with positive pelvic lymph nodes, parametrial involvement, or surgical margins; to explore associations between RT + CT; and to investigate histopathologic and clinical factors which might be predictive of recurrence.
METHODS: Histopathologic sections from biopsies and hysterectomies and clinical data were reviewed from patients with stage IA2, IB, or IIA cervical cancer treated with RT or RT + CT (cisplatin 70 mg/m2 plus fluorouracil 1000 mg/m2 every 3 weeks for four cycles). A univariate analysis was performed because the relatively small sample size limited the interpretation of a multivariate analysis.
RESULTS: Of the 268 enrolled women, 243 (RT = 116; RT + CT = 127) were evaluable. The beneficial effect of adjuvant CT was not strongly associated with patient age, histological type, or tumor grade. The prognostic significance of histological type, tumor size, number of positive nodes, and parametrial extension in the RT group was less apparent when CT was added. The absolute improvement in 5-year survival for adjuvant CT in patients with tumors < or =2 cm was only 5% (77% versus 82%), while for those with tumors >2 cm it was 19% (58% versus 77%). Similarly, the absolute 5-year survival benefit was less evident among patients with one nodal metastasis (79% versus 83%) than when at least two nodes were positive (55% versus 75%).
CONCLUSIONS: In this exploratory, hypothesis-generating analysis, adding CT to RT after radical hysterectomy, appears to provide a smaller absolute benefit when only one node is positive or when the tumor size is < 2 cm. Further study of the role of CT after radical hysterectomy in patients with a low risk of recurrence may be warranted.

Entities:  

Mesh:

Year:  2005        PMID: 15721417     DOI: 10.1016/j.ygyno.2004.11.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  58 in total

1.  Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate.

Authors:  Hiroko Machida; Takashi Iwata; Kaoru Okugawa; Koji Matsuo; Tsuyoshi Saito; Kyoko Tanaka; Kenichiro Morishige; Hiroaki Kobayashi; Kiyoshi Yoshino; Hideki Tokunaga; Tomoaki Ikeda; Makio Shozu; Nobuo Yaegashi; Takayuki Enomoto; Mikio Mikami
Journal:  Gynecol Oncol       Date:  2019-11-23       Impact factor: 5.482

Review 2.  Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer.

Authors:  Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

3.  Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.

Authors:  Bradley J Monk; Chunqiao Tian; Peter G Rose; Rachelle Lanciano
Journal:  Gynecol Oncol       Date:  2007-02-02       Impact factor: 5.482

4.  Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy.

Authors:  Kazunori Uegaki; Muneaki Shimada; Seiya Sato; Imari Deura; Jun Naniwa; Shinya Sato; Tetsuro Oishi; Hiroaki Itamochi; Tasuku Harada; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2013-04-17       Impact factor: 3.402

5.  Evaluation of the association between perineural invasion and clinical and histopathological features of cervical cancer.

Authors:  You-Sheng Wei; De-Sheng Yao; Ying Long
Journal:  Mol Clin Oncol       Date:  2016-06-24

6.  Downregulation of eukaryotic initiation factor 4A1 improves radiosensitivity by delaying DNA double strand break repair in cervical cancer.

Authors:  Shanhui Liang; Xingzhu Ju; Yuqi Zhou; Yiran Chen; Guihao Ke; Hao Wen; Xiaohua Wu
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

7.  Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer.

Authors:  F Heinzelmann; G Henke; M von Grafenstein; N Weidner; F Paulsen; A Staebler; S Brucker; M Bamberg; M Weinmann
Journal:  Strahlenther Onkol       Date:  2012-05-23       Impact factor: 3.621

8.  Long-term results and prognostic factors in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study.

Authors:  Wataru Kudaka; Yutaka Nagai; Takafumi Toita; Morihiko Inamine; Kozue Asato; Tomoko Nakamoto; Akihiko Wakayama; Takuma Ooyama; Akemi Tokura; Sadayuki Murayama; Yoichi Aoki
Journal:  Int J Clin Oncol       Date:  2012-08-18       Impact factor: 3.402

9.  Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.

Authors:  Mika Okazawa-Sakai; Takanori Yokoyama; Etsuko Fujimoto; Shinichi Okame; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara
Journal:  Int J Clin Oncol       Date:  2018-02-14       Impact factor: 3.402

10.  Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.

Authors:  Frederick B Stehman; Shamshad Ali; Henry M Keys; Laila I Muderspach; Weldon E Chafe; Donald G Gallup; Joan L Walker; Deborah Gersell
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.